ROME, July 11 — The period from the 1940s to the 1960s is now recorded as the ‘Golden Age’ of antibiotic discovery, a window in which most major classes of these drugs were identified from soil bacteria and synthetic chemistry. According to the historical record, that era produced treatments that fundamentally changed infectious disease medicine.
Streptomycin, discovered by Selman Waksman and Albert Schatz in 1943 from soil bacteria, became the first effective treatment for tuberculosis. The timeline shows that discovery was followed by a cascade of new classes. Tetracyclines arrived in 1948 with chlortetracycline, offering broad-spectrum coverage from *Streptomyces* bacteria. Chloramphenicol, isolated from *Streptomyces venezuelae*, was identified in 1947.
Macrolides such as erythromycin came from *Saccharopolyspora erythraea* in 1952. Glycopeptides including vancomycin were derived from *Amycolatopsis orientalis* in 1954. The quinolone class, represented by nalidixic acid in 1962, was synthetic rather than naturally derived. By the 1970s, the record shows, discovery had slowed markedly.
No new class of antibiotics was introduced until linezolid in 2000, followed by daptomycin in 2003. The pipeline has since dried up. Sources familiar with the data point to low profitability as a primary driver. According to the World Health Organization, only 12 new antibiotics were approved by the U.S. Food and Drug Administration from 2017 to 2021.
The gap between the Golden Age and the present represents a significant public health concern. Drug-resistant infections are rising globally, and the limited number of new approvals means fewer treatment options exist for patients with resistant strains. The WHO has repeatedly warned that the antibiotic pipeline is insufficient to meet current needs.
The economics of discovery
The slowdown in new antibiotic classes is not a scientific failure but an economic one, according to experts familiar with the pharmaceutical industry. Antibiotics are typically prescribed for short courses, limiting their revenue potential compared to chronic-disease medications. This makes investment in research and development less attractive for major drug companies.
The record shows that from the 1940s through the 1960s, researchers could still find novel compounds by systematically screening soil samples. That low-hanging fruit has largely been picked. The remaining microbial diversity is harder to access, and the cost of bringing a single new antibiotic to market now runs into the hundreds of millions of dollars.
What comes next
Researchers continue to explore alternative approaches, including bacteriophage therapy, antimicrobial peptides, and novel synthetic compounds. However, no new class of antibiotics has entered clinical practice since daptomycin in 2003. The timeline remains stalled.
The WHO has called for new incentives to stimulate antibiotic development, including pull mechanisms that reward companies for bringing effective drugs to market regardless of sales volume. Whether governments will act on those recommendations remains an open question.
Consult your doctor for medical advice.
